Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.53 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.51 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1053800 | 1.00 | F2 (0.55) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL4960887 | 1.00 | F2 (0.55) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL6026166 | 1.00 | F2 (0.55) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL28204655 | 1.00 | F2 (0.55) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL2119635 | 0.97 | F2 (0.57) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL2778546 | 0.97 | F2 (0.57) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL6850160 | 0.97 | F2 (0.57) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL6497247 | 0.97 | F2 (0.57) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL2778544 | 0.97 | F2 (0.57) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL9314374 | 0.94 | F2 (0.54) | F2OPRM1OPRD1OPRK1NPFFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| WO-2010146236-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORP. (FI) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | ITGA1, ITGB1, ITGA2B | F2 188/4885OPRM1 751/4885OPRD1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.